TAVR could be worth 100's million to AHZ. like i said its...

TAVR could be worth 100's million to AHZ. like i said its products are world class and funds will be lining up as they did at end of june when they put in $6 million at 30 cents.


MAJOR MILESTONE FOR TAVR AS TRIALS COMMENCE

Admedus Limited (ASX:AHZ) today reached a key milestone in the development of its patented Transcatheter Aortic Valve Replacement (TAVR) project with the commencement of animal trials and the first successful live implantation of its unique single-piece aortic heart valve.

As previously announced, Admedus has partnered with a leading European reference laboratory to conduct the “Experimental assessment of the Admedus valve - ovine model of aortic valve replacement” study which is using sheep to examine the safety and feasibility of Admedus’ unique 3D single-piece moulded valve in a living subject.

This follows on from the Company’s successful lab tests in which multiple 3D valves were run out to 400 million cycles (approx. 10 years of human use), with a competitor valve as a control.

Whilst the Admedus valves remained functional after 400 million cycles, the competitor valve showed significant fatigue at 250 million cycles. The first single-piece valve was implanted today, officially marking the start of the trial period, which is expected to last for approximately five months, and will involve multiple animals, before extending to larger animals (calves) for testing the valves in a TAVR setting. This is a major step forward for this strategic R&D project as it marks a critical point in the development roadmap into humans.

Admedus CEO Wayne Paterson was present in the laboratory for the first procedure and commented: “Today is a significant step for the TAVR project as we move into the next stage of development. It was exciting to observe the first-ever of our unique single-piece valves being placed inside a living heart. These experiments are being conducted by global leaders in the field and will provide critical insight for our Development team as we accelerate towards product commercialisation.”

By utilizing the ADAPT technology, Admedus will offer the first and only TAVR, with proven resistance to calcification and superior biomechanical control capabilities. This revolutionary combination of advantages, provide strong scientific rationale for Admedus TAVR to deliver predictable and improved outcomes. “This device has the potential to be a game-changer for patients, the Company and the US $3.5B TAVR market,” Mr Paterson added.